A Phase 3b Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses.

Trial Profile

A Phase 3b Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2011

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Therapeutic Use
  • Sponsors Graceway Pharmaceuticals
  • Most Recent Events

    • 08 Feb 2011 Results presented at the 69th Annual Meeting of the American Academy of Dermatology.
    • 30 Sep 2010 Results have been published in the Journal of Drugs in Dermatology, according to a Graceway Pharmaceuticals media release. Results were also detailed in this media release.
    • 30 Aug 2010 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top